Aviana Molecular Technologies welcomes John M. Starcher, Jr. Esq. as a Member of its Board of Directors
ORLANDO, Fla., March 13, 2018 /PRNewswire/ — Aviana Molecular Technologies, LLC, is pleased to announce the appointment of John M. Starcher, Jr. Esq. to its Board of Directors. Mr. Starcher is currently CEO of Mercy Health and oversees development of system strategies, operations for all 23 Mercy Health hospitals, and the integrated network across Ohio and Kentucky.
Mr. Starcher was President and CEO of Health Management Associates, an acute care delivery system with 71 hospitals across 15 states. He guided HMA through its successful sale to Community Health Systems. Mr. Starcher began his health care career in academic medicine, serving six years in leadership roles at the Medical College of Ohio, now the University of Toledo Medical Center. He has a bachelor’s degree in Business Administration from Bowling Green State University and a Doctorate in Jurisprudence from the University of Toledo. He has actively served as a director of over 16 boards.
Aviana has developed a cutting edge platform founded on the innovative adaptation of surface acoustic wave (SAW) sensors into a novel class of biosensors. The platform leverages the latest developments in cellular communications, semiconductor electronics, microfluidics and manufacturing methods to create a unique point-of-care diagnostic platform that is portable, cost-effective, and versatile.
“Mr. Starcher’s background in health care delivery is vital to the future success of our technology’s acceptance by health care providers,” said Dr. Vanaja V. Ragavan, President and CEO.
“Mr. Starcher expands the talent of the Aviana Board of Directors and we welcome his participation and guidance,” said William J. Link, Company Chairman of the Board of Directors.
“Aviana’s revolutionary point of care technology is poised to make a big difference for patients,” said John Starcher.
AMT (http://www.avianamolecular.com/) is a development stage diagnostic company working on an innovative, highly sensitive, and user-friendly platform technology, with an interest in developing a point-of-care (POC) diagnostic. AMT’s technology is simple, adaptable, and can be used for POC diagnosis for any number of biomarkers or infections. The platform can be used in both highly sophisticated health systems and resource-limited environments. Aviana believes that its technology can fill unmet medical needs worldwide, where POC diagnosis can positively impact human health.
SOURCE Aviana Molecular Technologies, LLC